The Asn505 mutation of the c-MPL gene, which causes familial essential thrombocythemia, induces autonomous homodimerization of the c-Mpl protein due to strong amino acid polarity.

We previously reported that a dominant-positive activating mutation (Asn505) in the transmembrane domain (TMD) of c-MPL, which encodes the thrombopoietin receptor, caused familial essential thrombocythemia. Here, we show that the Asn505 mutation induces both autonomous dimerization of c-Mpl and signal activation in the absence of its ligand. Signal activation was preserved in a truncated mutant of Asn505 that lacked the extracellular domain of c-MPL. We also found that the substitution of the amino acid (AA) residue at position 505 with others of strong polarity (Glu, Asp, or Gln) also resulted in activated dimerization without ligand stimulation. Overall, these data show that the Asn505 mutation transduced the signal through the autonomous dimerization of the c-MPL protein due to strong AA polarity. This finding provides a new insight into the mechanism of disease causation by mutations in the TMD of cytokine/hematopoietic receptors.

[1]  K. Hristova,et al.  The achondroplasia mutation does not alter the dimerization energetics of the fibroblast growth factor receptor 3 transmembrane domain. , 2006, Biochemistry.

[2]  W. Vainchenker,et al.  An amphipathic motif at the transmembrane-cytoplasmic junction prevents autonomous activation of the thrombopoietin receptor. , 2006, Blood.

[3]  K. Hristova,et al.  FGFR3 dimer stabilization due to a single amino acid pathogenic mutation. , 2006, Journal of molecular biology.

[4]  Michael W Parker,et al.  Model for growth hormone receptor activation based on subunit rotation within a receptor dimer , 2005, Nature Structural &Molecular Biology.

[5]  S. Iida,et al.  Familial essential thrombocythemia associated with a dominant-positive activating mutation of the c-MPL gene, which encodes for the receptor for thrombopoietin. , 2004, Blood.

[6]  S. Constantinescu,et al.  Active and inactive orientations of the transmembrane and cytosolic domains of the erythropoietin receptor dimer. , 2003, Molecular cell.

[7]  E. Mekada,et al.  Ligand-independent dimer formation of epidermal growth factor receptor (EGFR) is a step separable from ligand-induced EGFR signaling. , 2002, Molecular biology of the cell.

[8]  K. Kaushansky,et al.  The molecular and cellular biology of thrombopoietin: the primary regulator of platelet production , 2002, Oncogene.

[9]  C. Deber,et al.  Interhelical hydrogen bonds in the CFTR membrane domain , 2001, Nature Structural Biology.

[10]  H. Lodish,et al.  Ligand-independent oligomerization of cell-surface erythropoietin receptor is mediated by the transmembrane domain , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[11]  W. DeGrado,et al.  Polar side chains drive the association of model transmembrane peptides. , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[12]  William F. DeGrado,et al.  Asparagine-mediated self-association of a model transmembrane helix , 2000, Nature Structural Biology.

[13]  V. Broudy,et al.  Deletion of the extracellular membrane-distal cytokine receptor homology module of Mpl results in constitutive cell growth and loss of thrombopoietin binding. , 1999, Blood.

[14]  I. Wilson,et al.  Crystallographic evidence for preformed dimers of erythropoietin receptor before ligand activation. , 1999, Science.

[15]  I. Wilson,et al.  Erythropoietin receptor activation by a ligand-induced conformation change. , 1999, Science.

[16]  K. Kaushansky,et al.  Dissecting the thrombopoietin receptor: functional elements of the Mpl cytoplasmic domain. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[17]  R. D'Andrea,et al.  Activating mutations in cytokine receptors: implications for receptor function and role in disease. , 1997, Blood.

[18]  W. Reardon,et al.  A recurrent mutation, ala391glu, in the transmembrane region of FGFR3 causes Crouzon syndrome and acanthosis nigricans. , 1996, Journal of medical genetics.

[19]  G. Nolan,et al.  Identification of an oncogenic form of the thrombopoietin receptor MPL using retrovirus-mediated gene transfer. , 1996, Blood.

[20]  B. Bormann,et al.  Strong hydrogen bonding interactions involving a buried glutamic acid in the transmembrane sequence of the neu/erbB-2 receptor , 1996, Nature Structural Biology.

[21]  W. Alexander,et al.  Point mutations within a dimer interface homology domain of c‐Mpl induce constitutive receptor activity and tumorigenicity. , 1995, The EMBO journal.

[22]  H. Kitayama,et al.  Constitutively activating mutations of c-kit receptor tyrosine kinase confer factor-independent growth and tumorigenicity of factor-dependent hematopoietic cell lines. , 1995, Blood.

[23]  J. Mornon,et al.  Molecular cloning and characterization of MPL, the human homolog of the v-mpl oncogene: identification of a member of the hematopoietic growth factor receptor superfamily. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[24]  H. Lodish,et al.  Point mutation in the exoplasmic domain of the erythropoietin receptor resulting in hormone-independent activation and tumorigenicity , 1990, Nature.

[25]  W. Reardon,et al.  Spectrum of Craniosynostosis Phenotypes Associated with Novel Mutations at the Fibroblast Growth Factor Receptor 2 Locus , 1996, European journal of human genetics : EJHG.